Adds to executive focus on early clinical development and deepens medical and scientific partnership with clients DURHAM, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global
Adds to executive focus on early clinical development and deepens medical and scientific partnership with clients DURHAM, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global
Adds to executive focus on early clinical development and deepens medical and scientific partnership with clients DURHAM, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global
Adds to executive focus on early clinical development and deepens medical and scientific partnership with clients DURHAM, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global
Adds to executive focus on early clinical development and deepens medical and scientific partnership with clients DURHAM, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global
Adds to executive focus on early clinical development and deepens medical and scientific partnership with clients DURHAM, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global
